| |
Coef.
|
SE
|
DF
|
t
|
p
|
|---|
|
εcc (%)
|
−1.5540
|
0.3924
|
35
|
−3.9605
|
<.001
|
|
ESV (ml)
|
−0.2496
|
0.0446
|
43
|
−5.5980
|
<.001
|
|
ESFS (g/cm2)
|
−0.1584
|
0.0451
|
43
|
−3.5114
|
.0011
|
|
MMP7 (pg/ml)
|
−0.0014
|
0.0006
|
43
|
−2.4592
|
.018
|
|
sIL 4R (pg/ml)
|
0.0034
|
0.0014
|
44
|
2.4405
|
.0188
|
|
sRage (pg/ml)
|
−0.0502
|
0.0216
|
44
|
−2.3234
|
.0248
|
|
sTNFRI (pg/ml)
|
−0.0032
|
0.0015
|
44
|
−2.1340
|
.0385
|
|
sTNFRII (pg/ml)
|
−0.0008
|
0.0003
|
44
|
−2.4872
|
.0167
|
|
sVEGFR3 (pg/ml)
|
−0.0058
|
0.0022
|
44
|
−2.6162
|
.0121
|
- V1: first visit; V6: 1 year after maximal anthracycline therapy; εcc: Peak global longitudinal strain magnitude; ESV: End systolic volume; ESFS: End systolic fiber stress; MMP: Metalloproteinase; sILR: soluble interleukin receptor; sRage: receptor for advanced glycation end products; sTNFR: soluble receptor for TNF; sVEGFR: receptors for vascular endothelial growth factor
